Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer

被引:0
|
作者
Liu, Yuhan [1 ]
Zou, Yuhan [1 ]
Ye, Yangli [2 ]
Chen, Yong [3 ]
机构
[1] Shandong Second Med Univ, Sch Clin Med, Weifang, Peoples R China
[2] Shandong Second Med Univ, Coll Life Sci & Technol, Weifang, Peoples R China
[3] Shandong Second Med Univ, Key Lab Immune Microenvironm & Inflammatory Dis Re, Sch Basic Med Sci, Weifang, Peoples R China
来源
CANCER MEDICINE | 2024年 / 13卷 / 22期
关键词
classification; drug resistance; genomic alterations; signaling pathways; triple-negative breast cancer; HEDGEHOG SIGNALING PATHWAY; PEMBROLIZUMAB PLUS CHEMOTHERAPY; CISPLATIN RESISTANCE; STEM-CELLS; PACLITAXEL RESISTANCE; MUTATIONAL PROCESSES; THERAPEUTIC TARGET; PROMOTES; TRANSCRIPTION; MDA-MB-231;
D O I
10.1002/cam4.70410
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundTriple-negative breast cancer (TNBC) is a heterogeneous disease characterized by high aggressiveness, high malignancy, and poor prognosis compared to other breast cancer subtypes.ObjectiveThis review aims to explore recent advances in understanding TNBC and to provide new insights and potential references for clinical treatment.MethodsWe examined current literature on TNBC to analyze molecular subtypes, genetic mutations, signaling pathways, mechanisms of drug resistance, and emerging therapies.ResultsFindings highlight key aspects of TNBC's molecular subtypes, relevant mutations, and pathways, alongside emerging treatments that target drug resistance mechanisms.ConclusionThese insights into TNBC pathogenesis may help guide future therapeutic strategies and improve clinical outcomes for patients with TNBC.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Advanced Triple-Negative Breast Cancer
    Patel, Grisma
    Prince, Alison
    Harries, Mark
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [42] What is triple-negative breast cancer?
    Irvin, William J., Jr.
    Carey, Lisa A.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2799 - 2805
  • [43] Immunotherapy in Triple-Negative Breast Cancer
    Emens, Leisha A.
    CANCER JOURNAL, 2021, 27 (01): : 59 - 66
  • [44] Pembrolizumab in Triple-Negative Breast Cancer
    Altundag, Kadri
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (15): : 1435 - 1436
  • [45] A Review of Triple-Negative Breast Cancer
    Ismail-Khan, Roohi
    Bui, Marilyn M.
    CANCER CONTROL, 2010, 17 (03) : 173 - 176
  • [46] Triple-negative breast cancer: an update
    Boolbol, Susan K.
    Cate, Sarah P.
    BREAST CANCER MANAGEMENT, 2014, 3 (02) : 127 - 129
  • [47] Morphotypes of the triple-negative breast cancer
    Koleckova, M.
    Kolar, Z.
    Ehrmann, J.
    Korinkova, G.
    Trojanec, R.
    VIRCHOWS ARCHIV, 2017, 471 : S296 - S296
  • [48] Metastatic Triple-negative Breast Cancer
    Rakha, E. A.
    Chan, S.
    CLINICAL ONCOLOGY, 2011, 23 (09) : 587 - 600
  • [49] Chemoimmunotherapy for Triple-Negative Breast Cancer
    Slomski, Anita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (24): : 2521 - 2521
  • [50] Pembrolizumab for triple-negative breast cancer
    Stirrups, Robert
    LANCET ONCOLOGY, 2020, 21 (04): : E183 - E183